Literature DB >> 23837692

Investigation of the noncovalent binding mode of covalent proteasome inhibitors around the transition state by combined use of cyclopropylic strain-based conformational restriction and computational modeling.

Shuhei Kawamura1, Yuka Unno, Motohiro Tanaka, Takuma Sasaki, Akihito Yamano, Takatsugu Hirokawa, Tomoshi Kameda, Akira Asai, Mitsuhiro Arisawa, Satoshi Shuto.   

Abstract

To develop potent covalent inhibitors, the noncovalent interactions around the transition state to form covalent bonding should be optimized because the potency of the inhibitor can be depending on the energy of the transition state. Here, we report an efficient analysis of the noncovalent binding mode of a potent covalent proteasome inhibitor 3a around the transition state by a combined use of the chemical approach, i.e., the cyclopropylic strain-based conformational restriction, and the computational docking approach. Furthermore, we calculated the binding energy of a series of salinosporamide derivatives in the predicted noncovalent complex around the transition state with the simulation model of proteasome constructed in this study, which was well correlated to their pIC50. Thus, the proposed docking methods to predict the noncovalent binding mode around the transition state of covalent inhibitors will be helpful toward the development of covalent inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23837692     DOI: 10.1021/jm400542h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.

Authors:  Aibo Li; Haopeng Sun; Lei Du; Xiaoxin Wu; Jianqin Cao; Qidong You; Yuyan Li
Journal:  J Mol Model       Date:  2014-11-14       Impact factor: 1.810

2.  Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor.

Authors:  Takaaki Kobayashi; Akihiro Suemasa; Arisa Igawa; Soichiro Ide; Hayato Fukuda; Hiroshi Abe; Mitsuhiro Arisawa; Masabumi Minami; Satoshi Shuto
Journal:  ACS Med Chem Lett       Date:  2014-06-16       Impact factor: 4.345

3.  Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.

Authors:  Henry W B Johnson; Janet L Anderl; Erin K Bradley; John Bui; Jeffrey Jones; Shirin Arastu-Kapur; Lisa M Kelly; Eric Lowe; David C Moebius; Tony Muchamuel; Christopher Kirk; Zhengping Wang; Dustin McMinn
Journal:  ACS Med Chem Lett       Date:  2017-03-09       Impact factor: 4.345

4.  Synthesis of Resolvin E1 and Its Conformationally Restricted Cyclopropane Congeners with Potent Anti-Inflammatory Effect.

Authors:  Kohei Ishimura; Hayato Fukuda; Koichi Fujiwara; Ryuta Muromoto; Koki Hirashima; Yuto Murakami; Mizuki Watanabe; Jun Ishihara; Tadashi Matsuda; Satoshi Shuto
Journal:  ACS Med Chem Lett       Date:  2021-01-21       Impact factor: 4.345

Review 5.  Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.

Authors:  Romina A Guedes; Patrícia Serra; Jorge A R Salvador; Rita C Guedes
Journal:  Molecules       Date:  2016-07-16       Impact factor: 4.411

6.  Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.

Authors:  Grace E Hubbell; Jetze J Tepe
Journal:  RSC Chem Biol       Date:  2020-09-16

7.  Proteome-Wide Profiling of the Covalent-Druggable Cysteines with a Structure-Based Deep Graph Learning Network.

Authors:  Hongyan Du; Dejun Jiang; Junbo Gao; Xujun Zhang; Lingxiao Jiang; Yundian Zeng; Zhenxing Wu; Chao Shen; Lei Xu; Dongsheng Cao; Tingjun Hou; Peichen Pan
Journal:  Research (Wash D C)       Date:  2022-07-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.